Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia

Chronic lymphocytic leukemia (CLL) is common in both developed and developing nations where the need for inexpensive and convenient administration of therapy is apparent. Ocaratuzumab is a novel Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody (mAb) designed for effective antibody-dependen...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Cheney, Carolyn M, Stephens, Deborah M, Mo, Xiaokui, Rafiq, Sarwish, Butchar, Jonathan, Flynn, Joseph M, Jones, Jeffrey A, Maddocks, Kami, O’Reilly, Adrienne, Ramachandran, Abhijit, Tridandapani, Susheela, Muthusamy, Natarajan, Byrd, John C
Formato: Artigo
Idioma:Inglês
Publicado: Landes Bioscience 2014
Assuntos:
Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4011919/
https://ncbi.nlm.nih.gov/pubmed/24594909
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/mabs.28282
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares